Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. Eide CA, et al. Among authors: tyner jw. Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19. Cancer Res. 2011. PMID: 21505103 Free PMC article.
UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GG, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. DeRyckere D, et al. Among authors: tyner jw. Clin Cancer Res. 2017 Mar 15;23(6):1481-1492. doi: 10.1158/1078-0432.CCR-16-1330. Epub 2016 Sep 20. Clin Cancer Res. 2017. PMID: 27649555 Free PMC article.
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC. Weber H, et al. Among authors: tyner jw. Oncotarget. 2017 Apr 18;8(16):26169-26184. doi: 10.18632/oncotarget.15410. Oncotarget. 2017. PMID: 28412732 Free PMC article.
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Kurtz SE, et al. Among authors: tyner jw. Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7. Proc Natl Acad Sci U S A. 2017. PMID: 28784769 Free PMC article.
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.
Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Edwards V DK, et al. Among authors: tyner jw. Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15. Oncotarget. 2018. PMID: 29872489 Free PMC article.
215 results